Restart Life Sciences (HEAL) AI Stock Analysis

• Market Cap: C$3.29M
• Dividend Yield: N/A
• Average Volume (3M): 3.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 36,550,354
• 10 Day Avg. Volume: 5,146
• 30 Day Avg. Volume: 3,650
• PEG Ratio: -0.02
• Price to Book (P/B): -3.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.13 ▲(14.55% Upside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is primarily held down by very weak financial performance (pre-revenue, persistent losses/cash burn, and negative equity). Technical indicators are only moderately supportive and largely neutral, while valuation metrics provide limited support due to the negative P/E and no dividend.

Positive Factors

Low absolute debt burden

Modest reported debt limits near-term interest and refinancing pressure, preserving some financial flexibility. For a pre-revenue biotech, low nominal leverage reduces fixed-cost strain and gives management more optionality to fund R&D or seek strategic capital without large debt service obligations.

Negative Factors

Pre-revenue status

Zero reported revenue means the firm lacks recurring top-line cash generation, leaving the business highly dependent on external funding. Without visible commercial traction, execution risk and dilution risk remain elevated until products or partnerships produce sustainable revenue.

Restart Life Sciences Business Overview & Revenue Model

Company Description

Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mi...

Read more

Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mi...

How the Company Makes Money

null...

Restart Life Sciences Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	11.47K
Gross Profit	0.00	0.00	25.41K	-3.79K	-5.00K	1.73K
EBITDA	-1.27M	-656.20K	-1.20M	-1.84M	-2.68M	-25.23M
Net Income	-562.53K	224.75K	-1.22M	-3.76M	-2.68M	-25.23M
Balance Sheet
Total Assets	277.56K	190.40K	31.06K	296.79K	881.16K	3.05M
Cash, Cash Equivalents and Short-Term Investments	262.38K	169.95K	8.09K	266.52K	218.73K	2.14M
Total Debt	0.00	79.88K	0.00	0.00	0.00	0.00
Total Liabilities	214.89K	489.47K	841.66K	255.44K	422.06K	382.96K
Stockholders Equity	62.67K	-299.07K	-810.60K	41.34K	459.10K	2.66M
Cash Flow
Free Cash Flow	-328.58K	-71.77K	-277.53K	-1.44M	-1.95M	-422.11K
Operating Cash Flow	-328.58K	-71.77K	-277.53K	-1.44M	-1.95M	-856.53K
Investing Cash Flow	0.00	0.00	0.00	0.00	29.64K	2.90M
Financing Cash Flow	481.95K	75.00K	19.10K	1.49M	0.00	0.00

Restart Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENBI	47 Neutral	C$1.39M	-3.72	-107.76%	―	―	34.22%
HEAL	44 Neutral	C$3.29M	-1.36	―	―	―	―